	US 12,215,366 B2
	Compositions and methods for epigenome editing
Charles A. Gersbach, Chapel Hill, NC (US); and Isaac Hilton, Houston, TX (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Sep. 10, 2021, as Appl. No. 17/471,935.
Application 17/471,935 is a division of application No. 16/865,151, filed on May 1, 2020, granted, now 11,155,796.
Application 16/865,151 is a division of application No. 15/549,842, granted, now 10,676,726, issued on Jun. 9, 2020, previously published as PCT/US2016/017221, filed on Feb. 9, 2016.
Claims priority of provisional application 62/113,569, filed on Feb. 9, 2015.
Prior Publication US 2022/0098561 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 9/10 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01)

CPC C12N 9/22 (2013.01) [C12N 9/1029 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); C12Y 203/01048 (2013.01); C07K 2319/80 (2013.01); C12N 2310/20 (2017.05)]

12 Claims

1. A DNA targeting system comprising:

(1) a fusion protein comprising a first polypeptide domain and a second polypeptide domain, wherein the first polypeptide domain comprises a Clustered Regularly Interspaced Short Palindromic Repeats associated (Cas) protein comprising the sequence of SEQ ID NO: 1 and the second polypeptide domain comprises a peptide having histone acetyltransferase activity comprising the sequence of SEQ ID NO: 3, wherein the fusion protein activates transcription of a target gene; and

(2) at least one guide RNA (gRNA).